Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus HEMANGEOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus HEMANGEOL.
COREG CR vs HEMANGEOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Category C
Category C
Beta-Blocker
Beta-Blocker